Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit weight maintenance for diabetic patients. We performed a systematic review to evaluate its weight loss effect on obese/overweight patients without diabetes in randomized controlled trials (RCTs).
Methods: Literature updated to May 5, 2014 from Cochrane Library, MEDLINE, EMBASE and reference lists from relevant articles were identified. RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed. Studies lacking primary measurements were excluded. Three authors extracted data independently. Either fixed-effect or random-effect models were used to calculate weighted mean differences (WMDs), combined relative risks (RR) and 95% confidence interval (CI) in meta-analyses. Intertrial heterogeneity across studies was examined by I(2) and Q statistics.
Results: A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks. Participants in GLP-1RA groups achieved a larger weight loss than those in control groups (-2.85 kg, 95%CI -3.55 to -2.14), and liraglutide may work in a dose-dependent fashion. GLP-1RAs also reduced body mass index (BMI) and waist circumferences (WC) and benefited systolic blood pressure and triglyceride regulation. But GLP-1RAs were associated with increased nausea and vomiting events.
Conclusions: GLP-1 mimetics induce a weight loss in addition to BMI and WC reduction in obese/overweight adults without diabetes. Further long-term randomized trials and basic studies are required to investigate the mechanisms.
Keywords: glucagon-like peptide-1 mimetics; meta-analysis; non-diabetes; obesity; weight loss; 关键词：胰高血糖素样肽-1类似物，meta分析，非糖尿病，肥胖，减重。.
© 2014 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.